Docket Number:07A-980730
Inventor:Ta-Chau Chang, Chih-Chien Cho, Cheng-Chung Chang, Chi-Chih Kang, Zi-Fu Wang
Patent Status:US 8,431,708 、TW I382179、EP 002319842B1(GB、DE、CH、FR)
Abstract:
The large fluorescence contrast of BMVC derivatives between cancer cells and normal cells allow them to be attractive tumor markers for cancer diagnosis. Using these fluorescence probes, a simple, rapid, and non-invasive method is established for point-of-care screening of cancer cells at very low cost. Particularly, BMVC-8C is useful for early detection of limited cancer cells. Early detection is the key for better treatment of cancer and therefore improves the survival of the patient. This finding should be attractive to patient, clinician, government, and even insurance company.
Fields of Application:
1、Cancer diagnosis for outpatient,
2、Screening for routine test,
3、Follow-up for patient,
4、Simultaneous diagnosis during operation,
5、Service, such as establish the data base
and more for research, such as drug development, mitotracker, nucleus tracker, labeling, etc.
Advantages when compared to the existing technologies:
- Comparison with other tumor markers : Taking the advantage of BMVC and its derivatives, it is more easily synthesized and cheaper than antibody. In addition, application of BMVC and its derivatives can be applied to screen a great variety of cancers.
- The combination of our method and fine needle aspiration cytology can greatly improve the diagnostic accuracy and reduce the non-diagnostic cases.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
